Omar Boraie Accepts Rutgers’s Cancer Chair Challenge
Sam Boraie believes so strongly that the field of genomic science and precision medicine will find answers in the medical battle against cancer that he has pledged l.5 million dollars to establish a chair at Rutgers Cancer Research Center. The chair is a part of the ‘18 Chair Callenge’ Compaign of Rutgers University, and each endowed chair will be met by another l.5 million dollars, making the value of each chair worth 3 million dollars in the research field. It is considered the gold standard of endowment which guarantees that the Center is totally committed to this research.
The importance of precision medicine was noted in President Obama’s recent State of the Union Address when he announced a national Precision Medicine Initiative. According to Bloomberg, this involves research which analyzes and treats tumors on a genetic level and allows doctors to use individualized therapies for better results. It allows for grouping cancers into sub populations with similar characters. Genomic science provides new approaches, especially for rare tumors or those not responding to present treatments.
Omar Boraie, a giant in New Brunswick real estate, has long been committed to establishing the city and area as a “healthcare” city in New Jersey and the Eastern part of the country. In announcing the endowed chair, Cancer Institute Director Robert S. DiPaola, MD spoke of the impact it would have on research and treatment in a much wider area of the world.
Dr. Shridar Ganesan, an internationally regarded medical oncologist, has been named to the chair. He is a principal investigator of the precision medicine clinical trial at Rutgers Cancer Institute and associate professor at Rutgers Robert Wood Johnson Medical School. He came to the Institute in 2005 from the Dana Farber Cancer Institute at Harvard Medical School. Expressing how honored he was to be named to the chair, Dr. Ganesa explained that it has been determined that cancer is not a single disease but a collection of diseases. Genomic analysis allows for classifying the set of changes present in each cancer, allowing for more precise and timely treatment.
Rutgers is the State University of New Jersey, and the Rutgers Cancer Institute of New Jersey is the state’s only Comprehensive Cancer Center. Since it involves detection, treatment and care of patients, as well as serving as a resource for cancer prevention, it merges research with treatment, giving hope to many that engage in the Cancer War.